APO Research
Talk to an analyst

APO RESEARCH · REPORT

Urate-stimulating Excretion Agents

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Urate-stimulating Excretion Agents Market Outlook and Growth Opportunities 2026

27 December 2025195 pages

Choose your research edition.

Industry ResearchUrate-stimulating Excretion Agents Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Urate-stimulating Excretion Agents Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Urate-stimulating Excretion Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Urate-stimulating Excretion Agents Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Urate-stimulating Excretion Agents Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Urate-stimulating Excretion Agents market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Urate-stimulating Excretion Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Urate-stimulating Excretion Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Urate-stimulating Excretion Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Urate-stimulating Excretion Agents market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Urate-stimulating Excretion Agents market include Eisai, Teva, Towa Pharmaceutical, Lannett Company, Fuji Yakuhin, Excella and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Urate-stimulating Excretion Agents market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Urate-stimulating Excretion Agents and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Urate-stimulating Excretion Agents sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Urate-stimulating Excretion Agents market size, projected growth trends, production technologies, key applications, and end-use industries.

Urate-stimulating Excretion Agents Segment by Company

Eisai

Teva

Towa Pharmaceutical

Lannett Company

Fuji Yakuhin

Excella

AstraZeneca

Urate-stimulating Excretion Agents Segment by Type

Benzbromarone

Probenecid

Dotinurad

Lesinurad

Other

Urate-stimulating Excretion Agents Segment by Application

Retail Pharmacies

Hospitals and Clinics

Other

Urate-stimulating Excretion Agents Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Urate-stimulating Excretion Agents status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Urate-stimulating Excretion Agents market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Urate-stimulating Excretion Agents significant trends, drivers, influence factors in global and regions.

6. To analyze Urate-stimulating Excretion Agents competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urate-stimulating Excretion Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Urate-stimulating Excretion Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urate-stimulating Excretion Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Urate-stimulating Excretion Agents market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Urate-stimulating Excretion Agents industry.

Chapter 3: Detailed analysis of Urate-stimulating Excretion Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Urate-stimulating Excretion Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Urate-stimulating Excretion Agents in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Urate-stimulating Excretion Agents Industry Trends Table 2. Urate-stimulating Excretion Agents Industry Drivers Table 3. Urate-stimulating Excretion Agents Industry Opportunities and Challenges Table 4. Urate-stimulating Excretion Agents Industry Restraints Table 5. Global Urate-stimulating Excretion Agents Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Urate-stimulating Excretion Agents Revenue Share by Company (2021-2026) Table 7. Global Urate-stimulating Excretion Agents Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Urate-stimulating Excretion Agents Sales Volume Share by Company (2021-2026) Table 9. Global Urate-stimulating Excretion Agents Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Urate-stimulating Excretion Agents Company Ranking, (2024-2026) & (USD Million) Table 11. Global Urate-stimulating Excretion Agents Key Company Manufacturing Base & Headquarters Table 12. Global Urate-stimulating Excretion Agents Company, Product Type & Application Table 13. Global Urate-stimulating Excretion Agents Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Urate-stimulating Excretion Agents by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Benzbromarone Table 18. Significant Companies of Probenecid Table 19. Significant Companies of Dotinurad Table 20. Significant Companies of Lesinurad Table 21. Significant Companies of Other Table 22. Global Urate-stimulating Excretion Agents Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Urate-stimulating Excretion Agents Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Urate-stimulating Excretion Agents Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Urate-stimulating Excretion Agents Sales Volume Share by Type (2021-2026) Table 26. Global Urate-stimulating Excretion Agents Sales Volume Share by Type (2027-2032) Table 27. Global Urate-stimulating Excretion Agents Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Urate-stimulating Excretion Agents Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Urate-stimulating Excretion Agents Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Urate-stimulating Excretion Agents Sales Value Share by Type (2021-2026) Table 31. Global Urate-stimulating Excretion Agents Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Retail Pharmacies Table 33. Significant Companies of Hospitals and Clinics Table 34. Significant Companies of Other Table 35. Global Urate-stimulating Excretion Agents Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Urate-stimulating Excretion Agents Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Urate-stimulating Excretion Agents Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Urate-stimulating Excretion Agents Sales Volume Share by Application (2021-2026) Table 39. Global Urate-stimulating Excretion Agents Sales Volume Share by Application (2027-2032) Table 40. Global Urate-stimulating Excretion Agents Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Urate-stimulating Excretion Agents Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Urate-stimulating Excretion Agents Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Urate-stimulating Excretion Agents Sales Value Share by Application (2021-2026) Table 44. Global Urate-stimulating Excretion Agents Sales Value Share by Application (2027-2032) Table 45. Global Urate-stimulating Excretion Agents Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Urate-stimulating Excretion Agents Sales by Region (2021-2026) & (K Units) Table 47. Global Urate-stimulating Excretion Agents Sales Market Share by Region (2021-2026) Table 48. Global Urate-stimulating Excretion Agents Sales by Region (2027-2032) & (K Units) Table 49. Global Urate-stimulating Excretion Agents Sales Market Share by Region (2027-2032) Table 50. Global Urate-stimulating Excretion Agents Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Urate-stimulating Excretion Agents Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Urate-stimulating Excretion Agents Sales Value Share by Region (2021-2026) Table 53. Global Urate-stimulating Excretion Agents Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Urate-stimulating Excretion Agents Sales Value Share by Region (2027-2032) Table 55. Global Urate-stimulating Excretion Agents Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Urate-stimulating Excretion Agents Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Urate-stimulating Excretion Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Urate-stimulating Excretion Agents Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Urate-stimulating Excretion Agents Sales by Country (2021-2026) & (K Units) Table 60. Global Urate-stimulating Excretion Agents Sales Market Share by Country (2021-2026) Table 61. Global Urate-stimulating Excretion Agents Sales by Country (2027-2032) & (K Units) Table 62. Global Urate-stimulating Excretion Agents Sales Market Share by Country (2027-2032) Table 63. Global Urate-stimulating Excretion Agents Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Urate-stimulating Excretion Agents Sales Value Market Share by Country (2021-2026) Table 65. Global Urate-stimulating Excretion Agents Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Urate-stimulating Excretion Agents Sales Value Market Share by Country (2027-2032) Table 67. Eisai Company Information Table 68. Eisai Business Overview Table 69. Eisai Urate-stimulating Excretion Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Eisai Urate-stimulating Excretion Agents Product Portfolio Table 71. Eisai Recent Development Table 72. Teva Company Information Table 73. Teva Business Overview Table 74. Teva Urate-stimulating Excretion Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Teva Urate-stimulating Excretion Agents Product Portfolio Table 76. Teva Recent Development Table 77. Towa Pharmaceutical Company Information Table 78. Towa Pharmaceutical Business Overview Table 79. Towa Pharmaceutical Urate-stimulating Excretion Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Towa Pharmaceutical Urate-stimulating Excretion Agents Product Portfolio Table 81. Towa Pharmaceutical Recent Development Table 82. Lannett Company Company Information Table 83. Lannett Company Business Overview Table 84. Lannett Company Urate-stimulating Excretion Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Lannett Company Urate-stimulating Excretion Agents Product Portfolio Table 86. Lannett Company Recent Development Table 87. Fuji Yakuhin Company Information Table 88. Fuji Yakuhin Business Overview Table 89. Fuji Yakuhin Urate-stimulating Excretion Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Fuji Yakuhin Urate-stimulating Excretion Agents Product Portfolio Table 91. Fuji Yakuhin Recent Development Table 92. Excella Company Information Table 93. Excella Business Overview Table 94. Excella Urate-stimulating Excretion Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Excella Urate-stimulating Excretion Agents Product Portfolio Table 96. Excella Recent Development Table 97. AstraZeneca Company Information Table 98. AstraZeneca Business Overview Table 99. AstraZeneca Urate-stimulating Excretion Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. AstraZeneca Urate-stimulating Excretion Agents Product Portfolio Table 101. AstraZeneca Recent Development Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. Urate-stimulating Excretion Agents Distributors List Table 105. Urate-stimulating Excretion Agents Customers List Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Urate-stimulating Excretion Agents Product Image Figure 2. Global Urate-stimulating Excretion Agents Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Urate-stimulating Excretion Agents Sales Value (2021-2032) & (US$ Million) Figure 4. Global Urate-stimulating Excretion Agents Sales (2021-2032) & (K Units) Figure 5. Global Urate-stimulating Excretion Agents Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Urate-stimulating Excretion Agents Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Benzbromarone Image Figure 10. Probenecid Image Figure 11. Dotinurad Image Figure 12. Lesinurad Image Figure 13. Other Image Figure 14. Global Urate-stimulating Excretion Agents Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Urate-stimulating Excretion Agents Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Urate-stimulating Excretion Agents Sales Volume Share by Type (2021-2032) Figure 17. Global Urate-stimulating Excretion Agents Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Urate-stimulating Excretion Agents Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Urate-stimulating Excretion Agents Sales Value Share by Type (2021-2032) Figure 20. Retail Pharmacies Image Figure 21. Hospitals and Clinics Image Figure 22. Other Image Figure 23. Global Urate-stimulating Excretion Agents Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Urate-stimulating Excretion Agents Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Urate-stimulating Excretion Agents Sales Volume Share by Application (2021-2032) Figure 26. Global Urate-stimulating Excretion Agents Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Urate-stimulating Excretion Agents Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Urate-stimulating Excretion Agents Sales Value Share by Application (2021-2032) Figure 29. Global Urate-stimulating Excretion Agents Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Urate-stimulating Excretion Agents Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Urate-stimulating Excretion Agents Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Urate-stimulating Excretion Agents Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Urate-stimulating Excretion Agents Sales Value (2021-2032) & (US$ Million) Figure 34. North America Urate-stimulating Excretion Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Urate-stimulating Excretion Agents Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Urate-stimulating Excretion Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Urate-stimulating Excretion Agents Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Urate-stimulating Excretion Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Urate-stimulating Excretion Agents Sales Value (2021-2032) & (US$ Million) Figure 40. South America Urate-stimulating Excretion Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Urate-stimulating Excretion Agents Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Urate-stimulating Excretion Agents Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Urate-stimulating Excretion Agents Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Urate-stimulating Excretion Agents Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Benzbromarone
  • Probenecid
  • Dotinurad
  • Lesinurad
  • Other
Applications
  • Retail Pharmacies
  • Hospitals and Clinics
  • Other
Companies covered
  • Eisai
  • Teva
  • Towa Pharmaceutical
  • Lannett Company
  • Fuji Yakuhin
  • Excella
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Urate-stimulating Excretion Agents Sales Value (2021-2032)
  4. 1.2.2 Global Urate-stimulating Excretion Agents Sales Volume (2021-2032)
  5. 1.2.3 Global Urate-stimulating Excretion Agents Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Urate-stimulating Excretion Agents Market Dynamics
  1. 2.1 Urate-stimulating Excretion Agents Industry Trends
  2. 2.2 Urate-stimulating Excretion Agents Industry Drivers
  3. 2.3 Urate-stimulating Excretion Agents Industry Opportunities and Challenges
  4. 2.4 Urate-stimulating Excretion Agents Industry Restraints
3 Urate-stimulating Excretion Agents Market by Company
  1. 3.1 Global Urate-stimulating Excretion Agents Company Revenue Ranking in 2025
  2. 3.2 Global Urate-stimulating Excretion Agents Revenue by Company (2021-2026)
  3. 3.3 Global Urate-stimulating Excretion Agents Sales Volume by Company (2021-2026)
  4. 3.4 Global Urate-stimulating Excretion Agents Average Price by Company (2021-2026)
  5. 3.5 Global Urate-stimulating Excretion Agents Company Ranking (2024-2026)
  6. 3.6 Global Urate-stimulating Excretion Agents Company Manufacturing Base and Headquarters
  7. 3.7 Global Urate-stimulating Excretion Agents Company Product Type and Application
  8. 3.8 Global Urate-stimulating Excretion Agents Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Urate-stimulating Excretion Agents Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Urate-stimulating Excretion Agents Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Urate-stimulating Excretion Agents Market by Type
  1. 4.1 Urate-stimulating Excretion Agents Type Introduction
  2. 4.1.1 Benzbromarone
  3. 4.1.2 Probenecid
  4. 4.1.3 Dotinurad
  5. 4.1.4 Lesinurad
  6. 4.1.5 Other
  7. 4.2 Global Urate-stimulating Excretion Agents Sales Volume by Type
  8. 4.2.1 Global Urate-stimulating Excretion Agents Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Urate-stimulating Excretion Agents Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Urate-stimulating Excretion Agents Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Urate-stimulating Excretion Agents Sales Value by Type
  12. 4.3.1 Global Urate-stimulating Excretion Agents Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Urate-stimulating Excretion Agents Sales Value by Type (2021-2032)
  14. 4.3.3 Global Urate-stimulating Excretion Agents Sales Value Share by Type (2021-2032)
5 Urate-stimulating Excretion Agents Market by Application
  1. 5.1 Urate-stimulating Excretion Agents Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Hospitals and Clinics
  4. 5.1.3 Other
  5. 5.2 Global Urate-stimulating Excretion Agents Sales Volume by Application
  6. 5.2.1 Global Urate-stimulating Excretion Agents Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Urate-stimulating Excretion Agents Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Urate-stimulating Excretion Agents Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Urate-stimulating Excretion Agents Sales Value by Application
  10. 5.3.1 Global Urate-stimulating Excretion Agents Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Urate-stimulating Excretion Agents Sales Value by Application (2021-2032)
  12. 5.3.3 Global Urate-stimulating Excretion Agents Sales Value Share by Application (2021-2032)
6 Urate-stimulating Excretion Agents Regional Sales and Value Analysis
  1. 6.1 Global Urate-stimulating Excretion Agents Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Urate-stimulating Excretion Agents Sales by Region (2021-2032)
  3. 6.2.1 Global Urate-stimulating Excretion Agents Sales by Region: 2021-2026
  4. 6.2.2 Global Urate-stimulating Excretion Agents Sales by Region (2027-2032)
  5. 6.3 Global Urate-stimulating Excretion Agents Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Urate-stimulating Excretion Agents Sales Value by Region (2021-2032)
  7. 6.4.1 Global Urate-stimulating Excretion Agents Sales Value by Region: 2021-2026
  8. 6.4.2 Global Urate-stimulating Excretion Agents Sales Value by Region (2027-2032)
  9. 6.5 Global Urate-stimulating Excretion Agents Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Urate-stimulating Excretion Agents Sales Value (2021-2032)
  12. 6.6.2 North America Urate-stimulating Excretion Agents Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Urate-stimulating Excretion Agents Sales Value (2021-2032)
  15. 6.7.2 Europe Urate-stimulating Excretion Agents Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Urate-stimulating Excretion Agents Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Urate-stimulating Excretion Agents Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Urate-stimulating Excretion Agents Sales Value (2021-2032)
  21. 6.9.2 South America Urate-stimulating Excretion Agents Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Urate-stimulating Excretion Agents Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Urate-stimulating Excretion Agents Sales Value Share by Country, 2025 VS 2032
7 Urate-stimulating Excretion Agents Country-level Sales and Value Analysis
  1. 7.1 Global Urate-stimulating Excretion Agents Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Urate-stimulating Excretion Agents Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Urate-stimulating Excretion Agents Sales by Country (2021-2032)
  4. 7.3.1 Global Urate-stimulating Excretion Agents Sales by Country (2021-2026)
  5. 7.3.2 Global Urate-stimulating Excretion Agents Sales by Country (2027-2032)
  6. 7.4 Global Urate-stimulating Excretion Agents Sales Value by Country (2021-2032)
  7. 7.4.1 Global Urate-stimulating Excretion Agents Sales Value by Country (2021-2026)
  8. 7.4.2 Global Urate-stimulating Excretion Agents Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Urate-stimulating Excretion Agents Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Urate-stimulating Excretion Agents Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Urate-stimulating Excretion Agents Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai
  2. 8.1.1 Eisai Company Information
  3. 8.1.2 Eisai Business Overview
  4. 8.1.3 Eisai Urate-stimulating Excretion Agents Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Urate-stimulating Excretion Agents Product Portfolio
  6. 8.1.5 Eisai Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Urate-stimulating Excretion Agents Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Urate-stimulating Excretion Agents Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Towa Pharmaceutical
  14. 8.3.1 Towa Pharmaceutical Company Information
  15. 8.3.2 Towa Pharmaceutical Business Overview
  16. 8.3.3 Towa Pharmaceutical Urate-stimulating Excretion Agents Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Towa Pharmaceutical Urate-stimulating Excretion Agents Product Portfolio
  18. 8.3.5 Towa Pharmaceutical Recent Developments
  19. 8.4 Lannett Company
  20. 8.4.1 Lannett Company Company Information
  21. 8.4.2 Lannett Company Business Overview
  22. 8.4.3 Lannett Company Urate-stimulating Excretion Agents Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Lannett Company Urate-stimulating Excretion Agents Product Portfolio
  24. 8.4.5 Lannett Company Recent Developments
  25. 8.5 Fuji Yakuhin
  26. 8.5.1 Fuji Yakuhin Company Information
  27. 8.5.2 Fuji Yakuhin Business Overview
  28. 8.5.3 Fuji Yakuhin Urate-stimulating Excretion Agents Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Fuji Yakuhin Urate-stimulating Excretion Agents Product Portfolio
  30. 8.5.5 Fuji Yakuhin Recent Developments
  31. 8.6 Excella
  32. 8.6.1 Excella Company Information
  33. 8.6.2 Excella Business Overview
  34. 8.6.3 Excella Urate-stimulating Excretion Agents Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Excella Urate-stimulating Excretion Agents Product Portfolio
  36. 8.6.5 Excella Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Urate-stimulating Excretion Agents Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Urate-stimulating Excretion Agents Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Urate-stimulating Excretion Agents Value Chain Analysis
  2. 9.1.1 Urate-stimulating Excretion Agents Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Urate-stimulating Excretion Agents Sales Mode & Process
  6. 9.2 Urate-stimulating Excretion Agents Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Urate-stimulating Excretion Agents Distributors
  9. 9.2.3 Urate-stimulating Excretion Agents Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst